Serum Transthyretin

Serum Transthyretin
Nativi-Nicolau, Jose
2018-02-01 00:00:00
EDITORIAL Predictor of Amyloidosis Outcomes? See Article by Hanson et al Jose Nativi-Nicolau, MD The future depends on what you do today. ―Mahatma Gandhi biomarker is defined by the National Institutes of Health Biomarkers Def- initions Working Group as “a characteristic that is objectively measured A and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” Several biomarkers have been studied in recent years; however, few are used in clinical practice. According to the US Preventive Services Task Force, the potential impact of a novel risk factor is based on the following: (1) its predictive ability, (2) its preva- lence in the target population, (3) the number of intermediate-risk individuals who are reclassified as high risk when the risk factor is applied, and (4) the net benefit (benefits minus harms) that would accrue to these high-risk individuals if they were managed according to guidelines for high-risk patients. Amyloidosis involves the transformation of a precursor protein into an insol- uble extracellular fibril that interferes with the function of the organs affected (Figure). The most common precursors include immunoglobulin light chains (AL amyloidosis), wild-type transthyretins (ATTRwt), and genetically mutated trans- thyretins (ATTRm). The field
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngCirculation: Heart FailureWolters Kluwer Healthhttp://www.deepdyve.com/lp/wolters-kluwer-health/serum-transthyretin-6NNj00QGNy

Abstract

EDITORIAL Predictor of Amyloidosis Outcomes? See Article by Hanson et al Jose Nativi-Nicolau, MD The future depends on what you do today. ―Mahatma Gandhi biomarker is defined by the National Institutes of Health Biomarkers Def- initions Working Group as “a characteristic that is objectively measured A and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” Several biomarkers have been studied in recent years; however, few are used in clinical practice. According to the US Preventive Services Task Force, the potential impact of a novel risk factor is based on the following: (1) its predictive ability, (2) its preva- lence in the target population, (3) the number of intermediate-risk individuals who are reclassified as high risk when the risk factor is applied, and (4) the net benefit (benefits minus harms) that would accrue to these high-risk individuals if they were managed according to guidelines for high-risk patients. Amyloidosis involves the transformation of a precursor protein into an insol- uble extracellular fibril that interferes with the function of the organs affected (Figure). The most common precursors include immunoglobulin light chains (AL amyloidosis), wild-type transthyretins (ATTRwt), and genetically mutated trans- thyretins (ATTRm). The field